PPT-Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus

Progressive rises in weight and clinical obesity for TAFFTCDTG and TDFFTCDTG versus TDFFTCEFV ADVANCE and NAMSAL trials Andrew Hill Francois Venter Eric Delaporte Simiso Sokhela Charles. Massachusetts General Hospital. Boston, Massachusetts. State-of-the-ART in Antiretroviral Therapy: Optimal Initial Regimens in 2016. Washington, DC: August 23, 2016. Thanks to Alice Pau, Roger Bedimo and Marilyn Shi for assistance with slides. Estudio GS-US-311-1089 . Estudio GS-US-366-1216 . Estudio GS-US-366-1160 . . Diseño. Endpoints. Primario: proporción de pacientes . con C. V . < 50 c/mL a S48 (ITT, . snapshot. ) ; no inferioridad si el margen inferior de IC95% de dos colas para la diferencia = - 8%, poder 85%. ENCORE. EFV vs RPV. ECHO-THRIVE. STAR. EFV vs ETR. SENSE. DOR vs EFV. DRIVE-AHEAD. Design. Objectives. Non inferiority of DOR at W48: % HIV RNA < 50 c/mL by intention to treat, snapshot analysis (lower margin of the 95% CI for the difference = - 10%, . Treating and Preventing HIV in 2019: Interactive Cases From the Clinic(ians) Michael S. Saag , MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham introduction . of . DTG. Nandita Sugandhi. ICAP at Columbia University. No conflicts of interest to declare. Overview. Introducing . DTG in guidelines now. Programmatic Context. Eligible patient populations. www.hivguidelines.org. Purpose of . This Guideline. Provide a clear and concise roadmap for clinicians to follow in choosing from among several equally efficacious ART regimens based on individual patient characteristics and preferences.. Joseph J. Eron, Jr, MD. Professor of Medicine. University of North Carolina. Chapel Hill, North Carolina. Panelists. Constance Benson. Hyman Scott. Annie . Luetkemeyer. Robert . Schooley. Financial Relationships With Commercial Entities. Endpoints. Primary: proportion of patients with HIV RNA ≥ 50 c/mL at W48 (ITT-E, snapshot) ; non-inferiority if upper margin of the two-sided 95% CI for the difference = 4%, 97.3% power . Secondary: proportion of patients with HIV RNA < 50 c/mL at W48 (ITT-E, snapshot) ; non-inferiority if lower margin of the two-sided 95% CI for the difference = - 8%. –. NAIVE ADULTS WITH HIV-1 INFECTION: 96-WEEK RESULTS FROM THE GEMINI STUDIES. 1. Fundación Huesped, Buenos Aires, Argentina; . 2. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; . GEMINI 1 and GEMINI 2: Week 48 Data. DTG + 3TC . versus . DTG + TDF-FTC as Initial ART. GEMINI 1 and 2: Background. Source: Cahn P, et al. Lancet. 2019;393:143-55.. Study Design: GEMINI 1 and 2. Background. 1. ViiV Healthcare, Brentford, UK; . 2. Centre Hospitalier de Tourcoing, Tourcoing, France; . 3. Holdsworth House Medical Brisbane, Queensland, Australia; . 4. CHU Saint-Pierre, Brussels, Belgium; . 5. ACTG 5202. EFV versus ATV/r, both with ABC-3TC or TDF-FTC. ACTG 5202: Study Design. Source: . Daar. ES, et al. . Ann Intern Med. 2011;154:445-56. . EFV + ABC-3TC. (n = 465). ATV + RTV + ABC-3TC. (n = 463). ROCKET-1 Trial. Switch from EFV + ABC-3TC to EFV-TDF-FTC. ROCKET-1: Design. Source: Moyle GJ, et al. . PLoS. One. 2015;10:e0116297.. Immediate switch arm. EFV-TDF-FTC. . (n = 79). Delayed switch arm . RADAR Trial. Raltegravir. + Darunavir/r versus TDF-FTC + Darunavir/r. RADAR: Study Design. Source: . Bedimo. RJ, et al. . PLoS. One. 2014;9:e106221.. Darunavir QD + Ritonavir QD + Raltegravir BID .